文献
J-GLOBAL ID:202002280961935937
整理番号:20A2045338
放射線単独療法(SPIRAL-RT研究)後のステージIII化学放射線療法に不適格なNSCLC患者におけるデュルバルマブ治療の第II相試験の理論的根拠と設計【JST・京大機械翻訳】
Rationale and design of a phase II trial of durvalumab treatment in patients with NSCLC ineligible for stage III chemoradiotherapy following radiation monotherapy (SPIRAL-RT study)
著者 (9件):
Yamada Tadaaki
(Department of Pulmonary Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan)
,
Uchino Junji
(Department of Pulmonary Medicine, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Hirokoji-agaru, Kawaramachi-dori, Kamigyo-ku, Kyoto 602-0857, Japan)
,
Chihara Yusuke
(Department of Pulmonary Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan)
,
Shimamoto Takayuki
(Department of Pulmonary Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan)
,
Iwasaku Masahiro
(Department of Pulmonary Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan)
,
Tamiya Nobuyo
(Department of Pulmonary Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan)
,
Kaneko Yoshiko
(Department of Pulmonary Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan)
,
Kiyomi Fumiaki
(Statistics and Data Center, Clinical Research Support Center Kyushu, Fukuoka, Japan)
,
Takayama Koichi
(Department of Pulmonary Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan)
資料名:
Therapeutic Advances in Medical Oncology
(Therapeutic Advances in Medical Oncology)
巻:
12
ページ:
1758835920927841
発行年:
2020年
JST資料番号:
W5408A
ISSN:
1758-8340
資料種別:
逐次刊行物 (A)
記事区分:
原著論文
発行国:
アメリカ合衆国 (USA)
言語:
英語 (EN)